Search results for "Analogs"

showing 10 items of 53 documents

Temporally precise control of single-neuron spiking by juxtacellular nanostimulation

2017

Temporal patterns of action potentials influence a variety of activity-dependent intra- and intercellular processes and play an important role in theories of neural coding. Elucidating the mechanisms underlying these phenomena requires imposing spike trains with precisely defined patterns, but this has been challenging due to the limitations of existing stimulation techniques. Here we present a new nanostimulation method providing control over the action potential output of individual cortical neurons. Spikes are elicited through the juxtacellular application of short-duration fluctuating currents (“kurzpulses”), allowing for the sub-millisecond precise and reproducible induction of arbitr…

Male0301 basic medicine2-amino-5-phosphopentanoic acidPatch-Clamp TechniquesTime FactorsPhysiologyComputer scienceAction Potentialsgenetics [Luminescent Proteins]pharmacology [Valine]metabolism [Cytoskeletal Proteins]Mice0302 clinical medicineCortex (anatomy)physiology [Action Potentials]genetics [Nerve Tissue Proteins]6-Cyano-7-nitroquinoxaline-23-dioneNeuronsGeneral Neurosciencepharmacology [Excitatory Amino Acid Antagonists]Valinephysiology [Neurons]medicine.anatomical_structurepharmacology [6-Cyano-7-nitroquinoxaline-23-dione]FemaleSpike (software development)Neuroinformaticsgenetics [Synapsins]Models NeurologicalBiophysicsMice TransgenicNerve Tissue ProteinsOptogenetics03 medical and health sciencesmedicinedrug effects [Neurons]Animalsmetabolism [Synapsins]ddc:610metabolism [Luminescent Proteins]activity regulated cytoskeletal-associated proteingenetics [Cytoskeletal Proteins]analogs & derivatives [Valine]metabolism [Nerve Tissue Proteins]drug effects [Action Potentials]Somatosensory CortexSynapsinsElectric StimulationOptogeneticsCytoskeletal ProteinsLuminescent Proteins030104 developmental biologynervous systemInnovative Methodologycytology [Somatosensory Cortex]NeuronWhole cellExcitatory Amino Acid AntagonistsNeuroscience030217 neurology & neurosurgeryJournal of Neurophysiology
researchProduct

Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and de…

2015

Abstract Objectives Severe hypoglycemia is associated with cognitive decline and dementia in older persons with type 2 diabetes. The role of antidiabetic treatments on severe hypoglycemia is unknown in dementia. The aims were to determine the prevalence of severe hypoglycemic events and investigate associations among severe hypoglycemic and specific antidiabetic treatments (classes of oral agents and types of insulin analogs) in a large sample of nursing home patients with diabetes according to dementia status. Design Cross-sectional observational study. Setting A total of 150 nursing homes across Italy. Participants A total of 2258 patients with type 2 diabetes (dementia = 1138, no dementi…

Blood GlucoseMaleAgingSevere hypoglycemia dementia insulin analogs antidiabetic oral agents agingmedicine.medical_treatmentInsulin analogAdministration OralType 2 diabetesSeverity of Illness IndexInsulin AntagonistsReference ValuesOdds RatioPrevalenceHomes for the AgedInsulinReference ValueCognitive declineNursing (all)2901 Nursing (miscellaneous)General NursingAged 80 and overInsulin AntagonistMedicine (all)Health PolicyAging; Antidiabetic oral agents; Dementia; Insulin analogs; Severe hypoglycemia; Administration Oral; Age Distribution; Aged; Aged 80 and over; Blood Glucose; Confidence Intervals; Cross-Sectional Studies; Dementia; Diabetes Mellitus Type 2; Female; Homes for the Aged; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Antagonists; Italy; Logistic Models; Male; Middle Aged; Nursing Homes; Odds Ratio; Prevalence; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sex Distribution; Sulfonylurea Compounds; Nursing (all)2901 Nursing (miscellaneous); Health PolicyGeneral MedicineMiddle AgedPrognosisSulfonylurea CompoundNursing HomeItalyFemaleHumanmedicine.medical_specialtyLogistic ModelPrognosiHypoglycemiaelderly patientsRisk AssessmentAge DistributionInternal medicineDiabetes mellitusmedicineConfidence IntervalsDementiaHumansHypoglycemic AgentsSex DistributionAgedAntidiabetic oral agentCross-Sectional StudieSevere hypoglycemiaHypoglycemic Agentbusiness.industryInsulinOdds ratiomedicine.diseaseHypoglycemiaNursing HomesEndocrinologyCross-Sectional StudiesLogistic ModelsSulfonylurea CompoundsDiabetes Mellitus Type 2DementiaGeriatrics and GerontologybusinessConfidence IntervalBody mass indexJournal of the American Medical Directors Association
researchProduct

Efficacy of levetiracetam in the treatment of drug-resistant Rett Syndrome.

2010

Rett syndrome (RTT) is a progressive neurological disorder characterized by a wide spectrum of phenotypes. Epilepsy is reported to occur in 50–90% of patients with RTT; some develop medically refractory epilepsy. The aim of this study is to investigate the efficacy of levetiracetam (LEV) in drug-resistant patients with RTT. This prospective, pragmatic, open-label study consisted of an 8-week baseline period and a 6-month evaluation period. Efficacy variable was the mean frequency of monthly seizures before, and after 3 and 6 months of treatment with LEV. Eight female patients, aged 7.5–19 years (M12.8 ± 5) entered the study. Mean age at epilepsy onset was 25.8 ± 14.1 months. All patients sh…

Pediatricsmedicine.medical_specialtyLevetiracetamAdolescentMethyl-CpG-Binding Protein 2medicine.medical_treatmentRett syndromeNeurological disorderDrug Administration ScheduleCentral nervous system diseasedrug therapy/geneticsYoung AdultEpilepsyanalogs /&/ derivatives/therapeutic useSeizuresConvulsionmedicineRett SyndromeHumansgeneticsEEGProspective StudiesMyoclonic seizuresChildProspective cohort studyPsychiatryDrug-resistanceAnalysis of Variancebusiness.industryPatient SelectionFocal seizureElectroencephalographymedicine.diseaseAdolescent Analysis of Variance Anticonvulsants; therapeutic use Child Drug Administration Schedule Electroencephalography Female Humans Methyl-CpG-Binding Protein 2; genetics Patient Selection Piracetam; analogs /&/ derivatives/therapeutic use Prospective Studies Quality of Life Rett Syndrome; drug therapy/genetics Seizures; drug therapy/genetics Treatment Outcome Young AdultPiracetamSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeAnticonvulsantNeurologytherapeutic useQuality of LifeAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessmedicine.drug
researchProduct

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.

2015

Cardiovascular disease is a leading cause of death and reduced quality of life worldwide. Arterial vessels are a primary target for endothelial dysfunction and atherosclerosis, which is accompanied or even driven by increased oxidative stress. Recent research in this field identified different sources of reactive oxygen and nitrogen species contributing to the pathogenesis of endothelial dysfunction. According to lessons from the past, improvement of endothelial function and prevention of cardiovascular disease by systemic, unspecific, oral antioxidant therapy are obviously too simplistic an approach. Source- and cell organelle-specific antioxidants as well as activators of intrinsic antiox…

Antioxidantmedicine.medical_treatmentGlucagon-Like PeptidesInflammationDiseaseReviewBiologymedicine.disease_causeCatalysisAntioxidantsendothelial dysfunctionInorganic ChemistryPathogenesislcsh:Chemistrycardiovascular diseasemedicineAnimalsHumansImmunologic FactorsPhysical and Theoretical ChemistryEndothelial dysfunctionMolecular Biologylcsh:QH301-705.5Spectroscopyglucagon-like peptide analogsCause of deathInflammationOrganic ChemistryGeneral Medicinemedicine.diseaseComputer Science ApplicationsClinical trialOxidative Stresslcsh:Biology (General)lcsh:QD1-999Cardiovascular DiseasesImmunologyEndothelium Vascularmedicine.symptomdipeptidyl peptidase-4 inhibitorsOxidative stressInternational journal of molecular sciences
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Nelīdzsvara elektronu enerģijas sadalījuma funkcijas modelēšana periodiski modulētajam kvantu punktam

2017

Nanoelektroniskās ierīcēs ir plaši izmantojams kvantu punkts, kura īpašības ir atkarīgas no elektronu sadalījuma pa kvantu punkta enerģētiskajiem līmeņiem. Tunelēšanas procesi kvantu punktā bieži vien notiek režīmā, kurā elektroni nespēj relaksēt līdzsvara stāvoklī, kas var ietekmēt darbības efektivitāti. Otrais nozīmīgs faktors, ko mēs gribam ņemt vērā, ir elektronisko līmeņu spektra diskrēta daba, kas ietekmē sadalījuma formu. Šo divu efektu ietekme tiek izpētīta mūsu darbā, modelējot kvantu punkta-tuneļbarjeras-kontakta sistēmu ar Kinētisko Montekarlo metodi. Tiek simulēti elektronu nelīdzsvarotie sadalījumi kvantu punktā ar diskrēto līmeņu spektru, kas ļauj pētīt šo faktoru ietekmi uz n…

nelīdzsvara elektronu sadalījumsFermī-Diraka sadalījuma q-analogsFizikatunelēšanaKvantu punktselektronu uzlādes kontrasts
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Synthetic mRNAs with Superior Translation and Stability Properties

2012

The translational efficiency and stability of synthetic mRNA in both cultured cells and whole animals can be improved by incorporation of modified cap structures at the 5'-end. mRNAs are synthesized in vitro by a phage RNA polymerase transcribing a plasmid containing the mRNA sequence in the presence of all four NTPs plus a cap dinucleotide. Modifications in the cap dinucleotide at the 2'- or 3'-positions of m(7)Guo, or modifications in the polyphosphate chain, can improve both translational efficiency and stability of the mRNA, thereby increasing the amount and duration of protein expression. In the context of RNA-based immunotherapy, the latter is especially important for antigen producti…

RNA StabilityMessenger RNAchemistry.chemical_compoundRNA Cap AnalogsTranslational efficiencyChemistryRNA polymeraseProtein biosynthesisRNAContext (language use)Cell biology
researchProduct

Cuticular hydrocarbon profiles in Blattella germanica: effects of halofenozide, boric acid and benfuracarb

2006

1379-1176 (Print) Journal Article; In order to complete previous studies conducted on Blattella germanica, three insecticides from different groups were evaluated: boric acid, an inorganic compound, benfuracarb, a carbamate, and halofenozide, a non-steroidal ecdysone agonist. Boric acid (8.20%, LD50) and benfuracarb (2%, LD50) were incorporated into the diet and orally administrated to newly emerged adults of both sexes, while halofenozide (0.33%, LD50) was applied topically. Hydrocarbons extracts was made on bidistilled pentane from control and treated series sampled 6 days following treatment. Extracts was analyzed by gas chromatography. Data showed that cuticular profiles of control and …

OralMaleChromatographyHydrazines/*toxicityTime Factorsintegumentary systembeta-Alanine/*analogs & derivatives/toxicityHydrocarbons/*analysisBenzofurans/*toxicityBenzoic Acids/*toxicityLethal Dose 50TopicalInsecticides/*toxicityBoric Acids/*toxicityGasAdministrationAnimalsFemaleBlattellidae/chemistry/drug effects/growth & development
researchProduct